These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34414902)

  • 1. Role of Iron Chelators in Mucormycosis.
    Mahalmani V; Sarma P; Prakash A; Medhi B
    Indian J Pharmacol; 2021; 53(4):261-263. PubMed ID: 34414902
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy.
    Bhardwaj A; Roy V
    Indian J Pharmacol; 2021; 53(5):415-416. PubMed ID: 34854413
    [No Abstract]   [Full Text] [Related]  

  • 3. Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review.
    Singh A; Ahmad N; Varadarajan A; Vikram N; Singh TP; Sharma S; Sharma P
    Int J Biol Macromol; 2021 Sep; 187():988-998. PubMed ID: 34324905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
    Ibrahim AS; Gebermariam T; Fu Y; Lin L; Husseiny MI; French SW; Schwartz J; Skory CD; Edwards JE; Spellberg BJ
    J Clin Invest; 2007 Sep; 117(9):2649-57. PubMed ID: 17786247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in rhinocerebral mucormycosis: is iron the key?
    Bhargava P
    Neurol India; 2007; 55(4):416. PubMed ID: 18040125
    [No Abstract]   [Full Text] [Related]  

  • 6. [Iron and invasive fungal infection].
    Álvarez F; Fernández-Ruiz M; Aguado JM
    Rev Iberoam Micol; 2013; 30(4):217-25. PubMed ID: 23684655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
    Boelaert JR; Van Cutsem J; de Locht M; Schneider YJ; Crichton RR
    Kidney Int; 1994 Mar; 45(3):667-71. PubMed ID: 8196268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should statins be considered for the management of mucormycosis in COVID-19?
    Chatterjee S; Vardhan B; Singh DK; Maitra A; Ojha UK
    Diabetes Metab Syndr; 2021; 15(4):102162. PubMed ID: 34186353
    [No Abstract]   [Full Text] [Related]  

  • 9. Mucormycosis in COVID-19 recovered patients.
    Kumar A
    J Med Virol; 2022 Apr; 94(4):1272-1273. PubMed ID: 34905224
    [No Abstract]   [Full Text] [Related]  

  • 10. Palatal mucormycosis in a patient with SARS-CoV-2 infection.
    Venugopal A; Marya A
    CMAJ; 2021 Aug; 193(32):E1254. PubMed ID: 34400485
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
    Ibrahim AS; Gebremariam T; Luo G; Fu Y; French SW; Edwards JE; Spellberg B
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1768-70. PubMed ID: 21263057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
    Reed C; Ibrahim A; Edwards JE; Walot I; Spellberg B
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3968-9. PubMed ID: 17000743
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
    Spellberg B; Andes D; Perez M; Anglim A; Bonilla H; Mathisen GE; Walsh TJ; Ibrahim AS
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3122-5. PubMed ID: 19433555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression.
    Tabassum T; Araf Y; Moin AT; Rahaman TI; Hosen MJ
    Mol Biol Rep; 2022 Jan; 49(1):747-754. PubMed ID: 34709573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucormycosis in post-COVID-19 renal transplant patients: A lethal complication in follow-up.
    Meshram HS; Kute VB; Chauhan S; Desai S
    Transpl Infect Dis; 2021 Aug; 23(4):e13663. PubMed ID: 34081817
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
    Ibrahim AS; Spellberg B; Edwards J
    Curr Opin Infect Dis; 2008 Dec; 21(6):620-5. PubMed ID: 18978530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    Ibrahim AS; Edwards JE; Fu Y; Spellberg B
    J Antimicrob Chemother; 2006 Nov; 58(5):1070-3. PubMed ID: 16928702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhino-orbital-cerebral mucormycosis in COVID-19 patients - Taming the black evil with pharmacological weapons.
    Kaur K; Gurnani B
    Indian J Pharmacol; 2021; 53(5):417-419. PubMed ID: 34854414
    [No Abstract]   [Full Text] [Related]  

  • 19. Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.
    Elhamamsy S; Bayer T; Al-Kaffas M; Hatahet S; Grover M; Samdhani S; Nanda A; Gravenstein S
    R I Med J (2013); 2021 Oct; 104(8):19-21. PubMed ID: 34582509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Does Mucorales Benefit from the Dysregulated Iron Homeostasis During SARS-CoV-2 Infection?
    Lugito NPH; Cucunawangsih C
    Mycopathologia; 2021 Dec; 186(6):877-882. PubMed ID: 34623597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.